Last $1.66 USD
Change Today 0.00 / 0.00%
Volume 108.9K
As of 5:20 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

140 Intracoastal Pointe Drive

Suite 404

Jupiter, FL 33477

United States

Phone: 561-743-8333

Fax: 561-743-8343

Dyadic International, Inc. operates as a biotechnology company with operations in the United States, the Netherlands, and Poland. The company uses its patented and proprietary technologies to conduct research and development (R&D) and commercial activities for the discovery, development, manufacture, and sale of products and solutions for the bioenergy, industrial enzyme, and biopharmaceutical industries. The company involves in the licensing of its patented and proprietary technologies and the sale of its proprietary enzymes. Its research and development activities focus on its patented and proprietary fungal strains and associated technologies. It uses its Trichoderma and C1 fungal strains in the production of its industrial enzymes. It manufactures and sells liquid and dry enzyme products to global customers for use within the animal feed, food, brewing, alcohol, alternative fuels, textile, and pulp and paper industries. The company also utilizes an integrated technology platform based on its patented and proprietary C1 fungus (the C1 platform technology), which enables the development and manufacture of proteins and enzymes for various market opportunities. The C1 Platform Technology can also be used to screen for the discovery of novel genes and proteins. In addition to facilitating the development and production of enzymes, the C1 platform technology performs the same function of other biological products for the biopharmaceutical industry, such as antibodies, proteins, enzymes, and polypeptides. Strategic Alliances In December 2009, Dyadic International, Inc. announced that it has extended its collaboration with Scripps Research Institute by entering into an agreement with Scripps to re-annotate the genome of Dyadic's patented and proprietary C1 fungus ('C1'). History Dyadic International, Inc. was founded in 2002.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DYAI:US $1.66 USD 0.00

DYAI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Koninklijke DSM NV €50.28 EUR +0.07
Lonza Group AG SFr.116.40 CHF -0.30
Merck KGaA €69.52 EUR +1.00
Novozymes A/S kr259.90 DKK +2.30
Teva Pharmaceutical Industries Ltd $52.16 USD -0.25
View Industry Companies
 

Industry Analysis

DYAI

Industry Average

Valuation DYAI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYADIC INTERNATIONAL INC, please visit www.dyadic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.